Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina

Circulation. 2000 Aug 29;102(9):1007-13. doi: 10.1161/01.cir.102.9.1007.

Abstract

Background: Unstable angina is associated with enhanced lipid peroxidation and reduced antioxidant defenses. We have previously reported aspirin failure in the suppression of enhanced thromboxane (TX) biosynthesis in a subset of episodes of platelet activation in this setting. We tested the hypothesis that the in vivo formation of the F(2)-isoprostane 8-iso-prostaglandin (PG)F(2alpha), a bioactive product of arachidonic acid peroxidation, is enhanced in unstable angina and contributes to aspirin-insensitive TX biosynthesis.

Methods and results: Urine samples were obtained from patients with unstable angina (n=32), stable angina (n=32), or variant angina (n=4) and from 40 healthy subjects for the measurement of immunoreactive 8-iso-PGF(2alpha) and 11-dehydro-TXB(2). 8-Iso-PGF(2alpha) excretion was significantly higher in patients with unstable angina (339+/-122 pg/mg creatinine) than in matched patients with stable angina (236+/-83 pg/mg creatinine, P:=0.001) and control subjects (192+/-71 pg/mg creatinine, P:<0.0001). In patients with unstable angina, 8-iso-PGF(2alpha) was linearly correlated with 11-dehydro-TXB(2) excretion (rho=0.721, P:<0.0001) and inversely correlated with plasma vitamin E (rho=-0.710, P:=0. 004). Spontaneous myocardial ischemia in patients with variant angina or ischemia elicited by a stress test in patients with stable angina was not accompanied by any change in 8-iso-PGF(2alpha) excretion, thus excluding a role of ischemia per se in the induction of increased F(2)-isoprostane production.

Conclusions: These findings establish a putative biochemical link between increased oxidant stress and aspirin-insensitive TX biosynthesis in patients with unstable angina and provide a rationale for dose-finding studies of antioxidants in this setting.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angina, Unstable / drug therapy*
  • Angina, Unstable / metabolism
  • Antioxidants / therapeutic use*
  • Aspirin / therapeutic use*
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Dinoprost / analogs & derivatives*
  • Dinoprost / biosynthesis
  • Dinoprost / urine
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • F2-Isoprostanes
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Male
  • Membrane Proteins
  • Middle Aged
  • Oxidative Stress
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prostaglandin-Endoperoxide Synthases
  • Thromboxane A2 / biosynthesis*
  • Thromboxane A2 / blood
  • Time Factors

Substances

  • Antioxidants
  • F2-Isoprostanes
  • Isoenzymes
  • Membrane Proteins
  • Platelet Aggregation Inhibitors
  • 8-epi-prostaglandin F2alpha
  • Thromboxane A2
  • Dinoprost
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • PTGS1 protein, human
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Aspirin